What Are Celexa and Lexapro? Celexa (citalopram) and Lexapro (escitalopram) are antidepressants in the medication class called selective serotonin reuptake inhibitors (SSRIs). Citalopram is ...

Celexa, taken for depression, may cause side effects from mild issues like insomnia and weight changes to serious concerns such as suicidal thoughts, especially in young adults. Pre-existing ...

If you have depression, your doctor might suggest Celexa as a treatment option for you. Celexa is a prescription drug used to treat depression in adults ages 18 years and over. It comes as a tablet ...

On April 20, the FDA approved a revision to the safety labeling for citalopram hydrobromide and escitalopram oxalate (Celexa and Lexapro, respectively, made by Forest Laboratories) in tablet and oral ...

Citing increased risk of cardiac arrhythmias and a lack of therapeutic benefit associated with high doses of the selective serotonin reuptake inhibitor (SSRI) citalopram hydrobromide (Celexa), the FDA ...

The U.S. Food and Drug Administration (FDA) has reduced the maximum recommended dose of the antidepressant Celexa (citalopram) to 40 mg per day, warning that higher doses may trigger potentially fatal ...

Many people with depression also suffer from sleep problems. But in some patients the antidepressant Celexa (citalopram and generic) doesn't help relieve insomnia and might actually cause it, ...

A new study found that fluoxetine (Prozac) and citalopram (Celexa) treatment significantly inhibited disease progression of collagen-induced arthritis in mice. Researchers studied the anti-arthritic ...

The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Citalopram (Celexa (20 mg)) is a selective ...

NEW YORK, March 20 (Reuters) - Just weeks after prosecutors accused Forest Laboratories Inc of illegally marketing its anti-depressants Celexa and Lexapro to children and paying pediatricians ...

Every road to the cure or good treatment of a tough disease starts with a promising path. Unfortunately, most of those paths turn into blind alleys, and only solid research can discern the difference.